Inflammatory Signaling in Kidney Stromal Cells Driving Interstitial Fibrosis
肾基质细胞中的炎症信号驱动间质纤维化
基本信息
- 批准号:10371183
- 负责人:
- 金额:$ 26.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-09 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcute Renal Failure with Renal Papillary NecrosisAllelesAutomobile DrivingAutophagocytosisBiomedical EngineeringBlood VesselsBone MarrowCell Differentiation processCell ProliferationCellsCellular biologyChemistryCicatrixComplexDataDevelopmentDown-RegulationEnd stage renal failureEventFibroblastsFibrosisGeneticGenetic TranscriptionGoalsHematopoieticHumanIL1R1 geneIL6 geneIRAK4 geneImmune signalingImpairmentIn VitroInflammationInflammatoryInjury to KidneyInterleukin-1 ReceptorsInterleukin-1 betaInterleukinsIschemiaKidneyKnock-inLaboratoriesLigandsLoxP-flanked alleleMediatingModelingMolecularMolecular BiologyMusMutationMyofibroblastNF-kappa BNamesNephronsOrganoidsPericytesPharmacologyPhosphotransferasesProcessProductionProfibrotic signalProtein KinaseProtein-Serine-Threonine KinasesProteinsProtocols documentationPublishingReceptor SignalingRenal functionReperfusion InjuryReportingResearchRestRoleShapesSignal TransductionStromal CellsTLR2 geneTestingTherapeuticTissuesToll-like receptorsTranscriptional ActivationTransgenic MiceWorkbasecell typecomparativecytokinefibrous proteinin vivoinnovationinterstitialischemic injurykidney fibrosismouse modelmulticatalytic endopeptidase complexnegative affectnovelnovel therapeuticspre-clinicalpreventprogramsrational designreconstitutionrenal damagerenal ischemiaresponsescaffoldsmall moleculesmall molecule inhibitorsynthetic proteintargeted treatmenttherapeutically effectivetool
项目摘要
PROJECT SUMMARY/ABSTRACT
A growing body of evidence indicates that molecular signaling mechanisms mediated by the myddosome
complex in kidney stromal cells, drive fibrosis triggered by interleukin 1b (IL1b) and Toll-like receptor (TLR)
ligands. Work from our laboratory and by others has shown that signaling mechanisms associated with IRAK4,
a key component of the stromal cell myddosome, contributes to the development of renal fibrosis after acute
kidney injury. IRAK4, therefore, emerges as a suitable target for much needed therapies targeting renal
fibrosis. In order to effectively target IRAK4, however a deeper understanding of its mechanisms is needed.
IRAK4 has been shown to possess two distinct functions, one as a serine/threonine kinase and the other as a
structural scaffold necessary for myddosome formation. Importantly, the role of IRAK4 as a myddosome
scaffold is necessary for its kinase activity, but the latter is not necessary for myddosome-mediated signaling.
We have reported that pharmacologic inhibition of IRAK4 kinase activity with a selective small molecule
significantly reduces pro-fibrotic stromal cell activity, including proliferation and differentiation into
myofibroblasts, both ex vivo in response to IL1β stimulation, and in vivo after ischemic kidney injury. Our data
further indicated that those profibrotic mechanisms depend on stabilization and activation of the transcriptional
regulator MYC via a mechanism involving IL1R-driven autophagy. On the contrary, inhibition of IRAK4 kinase
activity did not result in abrogation of synthesis and secretion of NF-κB-regulated inflammatory cytokines
IL1β and IL6 in kidney stromal cells. Those results are in keeping with previous reports indicating that NF-kB
activation by IRAK4 is myddosome-mediated and only partially dependent on IRAK4 kinase activity. The
objective of this project is to dissect the molecular mechanisms through which IRAK4 mediates kidney fibrosis,
by assessing the distinct contribution of kinase-dependent versus myddosome-dependent IRAK4 signaling
mechanisms. The long-term goal of these studies is to set the pre-clinical basis for novel therapeutics that can
ameliorate both renal fibrosis and local inflammation through blockage of stromal cell pro-fibrotic and pro-
inflammatory activities. The central hypothesis is that following acute kidney injury IRAK4 kinase activity in
stromal cells is necessary for pro-fibrotic mechanisms, while kinase-independent IRAK4-mediated myddosome
assembly is necessary for inflammatory cytokine production by those cells during the process of kidney
scarring. Our rationale for the research strategy proposed is based on a combination of genetic ablation
strategies to study IRAK4 kinase domain-independent mechanisms, along with cutting-edge bioengineered
human kidney organoids for the study of the nephron interstitial microenvironment in the absence of confusing
hematopoietic immune signals. In addition, we propose the use of novel therapeutic chemistry shown to be
effective for inducible targeted degradation of IRAK4 in vivo, abrogating myddosome formation. Our three
specific aims will test three major hypotheses: (Aim 1) IRAK4 kinase function is necessary for profibrotic
mechanisms of kidney stromal cells post-AKI; (Aim 2) signaling via IL1R/IRAK4 stabilizes MYC via a mechanism
involving stromal cell autophagy and degradation of SQSTM1/P62; (Aim 3) pharmacologic abrogation of IRAK4
using a synthetic protein degrader molecule will impair stromal cell myddosome formation and ameliorate IRI-
induced kidney fibrosis. Collectively, these studies will provide critical experimental and mechanistic basis for a
rational design of therapies targeting IRAK4 in renal fibrosis.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dario Lemos其他文献
Dario Lemos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dario Lemos', 18)}}的其他基金
Elucidation of Tumor Resistance Mechanisms in Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma for the Design of Novel Nanotherapies
阐明结节性硬化症相关肾血管平滑肌脂肪瘤的肿瘤抵抗机制,用于设计新型纳米疗法
- 批准号:
10585048 - 财政年份:2023
- 资助金额:
$ 26.85万 - 项目类别:
Detection of aging mechanisms of nephron degeneration using nanoscale pathology
使用纳米病理学检测肾单位变性的衰老机制
- 批准号:
9436548 - 财政年份:2018
- 资助金额:
$ 26.85万 - 项目类别: